Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash from Financing Activities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Cash from Financing Activities for 11 consecutive years, with $96.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 2243.07% to $96.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 447.66% year-over-year, with the annual reading at $1.1 billion for FY2025, 447.66% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $96.9 million at BeOne Medicines, down from $961.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $3.3 billion in Q4 2021, with the low at -$110.4 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $259.3 million, with a median of $35.3 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 163.86% in 2023, then soared 7491.79% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $3.3 billion in 2021, then crashed by 103.36% to -$110.4 million in 2022, then skyrocketed by 414.45% to $347.0 million in 2023, then crashed by 101.3% to -$4.5 million in 2024, then surged by 2243.07% to $96.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $96.9 million, $961.3 million, and $35.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.